Centre for the Development of Industrial Technology

ARTHEx Biotech Announces Closing of €42 M Series B Financing to Advance ATX-01, its Novel Treatment for Myotonic Dystrophy Type 1 (DM1)

Retrieved on: 
onsdag, maj 3, 2023
European Innovation Council, MBNL, Industrial technology, Venture round, CSO, DM1, MicroRNA, Myotonic dystrophy, Muscle weakness, Development, Centre for the Development of Industrial Technology, CDTI, Patient, Growth, EIC, Disease, Pharmaceutical industry

VALENCIA, Spain, May 3, 2023 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs announced the closing of its €42 million Series B financing round led by Columbus Venture Partners, with participation from new investors, the European Innovation Council (EIC), Hadean Ventures, and Sound Bioventures. Existing investors Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI) through its Innvierte program, also participated in the financing. 

Key Points: 
  • Existing investors Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI) through its Innvierte program, also participated in the financing.
  • The Series B proceeds will be used to advance its lead compound, ATX-01, an antimiR designed to target microRNA 23b (miR-23b), to a Phase I/IIa clinical trial for the treatment of Myotonic Dystrophy Type 1 (DM1).
  • There are currently no disease-modifying treatments for DM1, which affects at least 40,000 people in the U.S and 70,000 in Europe.
  • In connection with the financing, ARTHEx' present Chairman of the Board of Directors, Dr. Frédéric Legros, has been appointed Chief Executive Officer.

The 2nd annual Connecting Green Hydrogen Europe 2023 will Take Place in Madrid, Spain

Retrieved on: 
tisdag, januari 10, 2023
Hydrogen, Hive, CDTI, Multimedia, IPP, ENGIE, European Commission, Engineering, Shell, Centre for the Development of Industrial Technology, Demography, International Renewable Energy Agency, Royal commission, Enel Green Power, Exhibition, Development, PRF, CNH2, Air Liquide, BASF, World Steel Association, CGHE, Hotel Riu Plaza Guadalajara, Union of International Mountain Leader Associations, RHI Magnesita, EWE, Associate, Ministry (collective executive), INEOS, PGNiG, Oil, Industrial technology, Ministry of the Ecological Transition (France), OMV, App Store (iOS/iPadOS), EDP Renováveis, Gas, E.ON, Naturgy, IRENA, European Association of Bodies and Public Organizations of Security and Defense, Renewable energy, Woman, Aperam, BP

MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.

Key Points: 
  • MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.
  • As a region's high-end conference & exhibition toward a green hydrogen future in Europe, Connecting Green Hydrogen Europe 2023 will bring together the entire hydrogen value chain to focus on developing solutions and innovations for low-carbon hydrogen production, efficient storage and distribution, and applications in various stationary and mobile applications in Europe.
  • CGHE2023 creates a tailored setting where senior decision-makers could network, share pragmatic approaches supporting the green hydrogen growth, and green hydrogen industry hub in Europe, foster international partnerships to facilitate green hydrogen economics.
  • As the premier event focusing on the hydrogen industry, Connecting Green Hydrogen Europe has been held successfully in Madrid for two consecutive years.

The 2nd annual Connecting Green Hydrogen Europe 2023 will Take Place in Madrid, Spain

Retrieved on: 
tisdag, januari 10, 2023
Hydrogen, Hive, Shell, CDTI, Hotel Riu Plaza Guadalajara, Union of International Mountain Leader Associations, Centre for the Development of Industrial Technology, Demography, RHI Magnesita, PGNiG, Oil, International Renewable Energy Agency, Industrial technology, Ministry of the Ecological Transition (France), OMV, App Store (iOS/iPadOS), Royal commission, EDP Renováveis, European Association of Bodies and Public Organizations of Security and Defense, IPP, EWE, Enel Green Power, Exhibition, ENGIE, Development, PRF, Associate, Gas, CNH2, European Commission, Ministry (collective executive), Air Liquide, BASF, INEOS, Engineering, E.ON, Naturgy, IRENA, World Steel Association, CGHE, Renewable energy, BP, Woman, Aperam

MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.

Key Points: 
  • MADRID, Jan. 10, 2023 /PRNewswire/ -- Connecting Green Hydrogen Europe (CGHE2023) 2023 – Advancing Towards Europe's Green Hydrogen Roadmap – is taking place on 5th – 6th July 2023 at Riu Plaza España Madrid, Spain.
  • As a region's high-end conference & exhibition toward a green hydrogen future in Europe, Connecting Green Hydrogen Europe 2023 will bring together the entire hydrogen value chain to focus on developing solutions and innovations for low-carbon hydrogen production, efficient storage and distribution, and applications in various stationary and mobile applications in Europe.
  • CGHE2023 creates a tailored setting where senior decision-makers could network, share pragmatic approaches supporting the green hydrogen growth, and green hydrogen industry hub in Europe, foster international partnerships to facilitate green hydrogen economics.
  • As the premier event focusing on the hydrogen industry, Connecting Green Hydrogen Europe has been held successfully in Madrid for two consecutive years.

Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

Retrieved on: 
onsdag, december 14, 2022
Chemistry, DM1, Industrial technology, Drug discovery, Scientific Advice Mechanism, Development, Food, IND, Muscle, EMA, Toxicology, Patient, Orphan drug, Myotonic dystrophy, Disease, FDA, Fatigue, CMC, CTA, MicroRNA, ODD, European Medicines Agency, Hypersomnia, Science, CDTI, Tissue, Food and Drug Administration Amendments Act of 2007, FIH, Centre for the Development of Industrial Technology, Pharmaceutical industry

Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.

Key Points: 
  • Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.
  • Myotonic dystrophy type 1 (DM1) is a highly disabling disease affecting more than one million people worldwide.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.
  • Arthex Biotech's investors are Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI).

Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

Retrieved on: 
onsdag, december 14, 2022
Chemistry, DM1, Industrial technology, Drug discovery, Scientific Advice Mechanism, Development, Food, IND, Muscle, EMA, Toxicology, Patient, Orphan drug, Myotonic dystrophy, Disease, FDA, Fatigue, CMC, CTA, MicroRNA, ODD, European Medicines Agency, Hypersomnia, Science, CDTI, Tissue, Food and Drug Administration Amendments Act of 2007, FIH, Centre for the Development of Industrial Technology, Pharmaceutical industry

Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.

Key Points: 
  • Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.
  • Myotonic dystrophy type 1 (DM1) is a highly disabling disease affecting more than one million people worldwide.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.
  • Arthex Biotech's investors are Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI).

Arthex Biotech Appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board

Retrieved on: 
måndag, november 28, 2022
Doctor of Philosophy, CDTI, Executive, University, MicroRNA, Corporation, Myotonic dystrophy, Knowledge, Biotechnology, Patient, Business development, Centre for the Development of Industrial Technology, Eppendorf (company), The Advisory Board Company, Molecular biology, NEOMA Business School, Development, Industrial technology, Valneva SE, Paris Diderot University, Pharmaceutical industry, Management

Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.

Key Points: 
  • Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.
  • Beatriz Llamus, CEO of Arthex Biotech, commented: "We are very pleased to have Frdricjoin us as Arthex Biotech's Executive Chairman of the Board.
  • Dr. Legros, the new Executive Chairman of the Board of Directors, said, "Arthex Biotech is a very promising company with an exciting lead program targeting diseases with high unmet medical needs in which microRNAs play a role.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.

Arthex Biotech Appoints Frédéric Legros, Ph.D., as Executive Chairman of the Board

Retrieved on: 
måndag, november 28, 2022
Doctor of Philosophy, CDTI, Executive, University, MicroRNA, Corporation, Myotonic dystrophy, Knowledge, Biotechnology, Patient, Business development, Centre for the Development of Industrial Technology, Eppendorf (company), The Advisory Board Company, Molecular biology, NEOMA Business School, Development, Industrial technology, Valneva SE, Paris Diderot University, Pharmaceutical industry, Management

Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.

Key Points: 
  • Dr. Frdric Legros is an established biotech leader with more than 15 years of Corporate & Business Development experience in the biotechnology industry.
  • Beatriz Llamus, CEO of Arthex Biotech, commented: "We are very pleased to have Frdricjoin us as Arthex Biotech's Executive Chairman of the Board.
  • Dr. Legros, the new Executive Chairman of the Board of Directors, said, "Arthex Biotech is a very promising company with an exciting lead program targeting diseases with high unmet medical needs in which microRNAs play a role.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.

CDTi Advanced Materials, Inc. Reports Year-End 2020 Financial Results

Retrieved on: 
torsdag, april 22, 2021
Common rail, Catalyst, DTI, Centre for the Development of Industrial Technology

b'OXNARD, Calif., April 22, 2021 /PRNewswire/ --CDTi Advanced Materials, Inc. (OTC: CDTI) ("CDTi" or "the Company"), a leader in advanced catalyst technology, reported its financial results for the year ended December 31, 2020.\nMatthew Beale, the Company\'s CEO, stated, "Despite a challenging trading environment globally, our 2020 results reflect the positive impact of our repositioning and creation of a solid foundation for future profitability and growth.

Key Points: 
  • b'OXNARD, Calif., April 22, 2021 /PRNewswire/ --CDTi Advanced Materials, Inc. (OTC: CDTI) ("CDTi" or "the Company"), a leader in advanced catalyst technology, reported its financial results for the year ended December 31, 2020.\nMatthew Beale, the Company\'s CEO, stated, "Despite a challenging trading environment globally, our 2020 results reflect the positive impact of our repositioning and creation of a solid foundation for future profitability and growth.
  • Our zero and low-PGM catalyst technology is highly relevant in these markets as is our high temperature catalyst coating capability.
  • CDTi believes that it possesses market leading expertise in catalyst design, engineering and coating for combustion and energy storage applications.
  • All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.\n'